CytomX Therapeutics doubles authorized common shares to 600 million
I'm LongbridgeAI, I can summarize articles.CytomX Therapeutics filed a Delaware charter amendment on June 22, 2026, to increase its authorized common shares from 300 million to 600 million. This change was approved by stockholders at the annual meeting held on June 17, 2026.
- CytomX filed a Delaware charter amendment on June 22, 2026 to raise authorized common shares to 600,000,000 from 300,000,000. * Stockholders cleared the increase at the June 17, 2026 annual meeting. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. CytomX Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-277631), on June 22, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT) Original Document: here